Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Namenda neuropathic pain trial

Executive Summary

Forest will initiate a new Phase II trial of Namenda (memantine) for neuropathic pain, with a possible NDA submission by 2006. A previous Phase III study failed to show overall statistical significance in primary endpoint of nocturnal pain, although there was improvement in weekly assessments. Namenda was approved for treatment of moderate to severe Alzheimer's disease Oct. 16 (1"The Pink Sheet" Oct. 20, 2003, p. 3)...

You may also be interested in...

Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December

Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent

PCPC Exploring Solutions With Chinese Authorities To Facilitate Cruelty-Free Cosmetic Imports

France plans to begin issuing manufacturing quality certificates so firms can import ordinary cosmetics into China without animal testing under a 2020 draft regulation. The Personal Care Products Council is working to find a comparable solution for US manufacturers.

Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis

The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts